Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Rev. bras. cir. cardiovasc ; 32(2): 96-103, Mar.-Apr. 2017. tab
Artigo em Inglês | LILACS | ID: biblio-843481

RESUMO

Abstract INTRODUCTION: The mortality due to cardiogenic shock complicating acute myocardial infarction (AMI) is high even in patients with early revascularization. Infusion of low dose recombinant human brain natriuretic peptide (rhBNP) at the time of AMI is well tolerated and could improve cardiac function. OBJECTIVE: The objective of this study was to evaluate the hemodynamic effects of rhBNP in AMI patients revascularized by emergency percutaneous coronary intervention (PCI) who developed cardiogenic shock. METHODS: A total of 48 patients with acute ST segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock and whose hemodynamic status was improved following emergency PCI were enrolled. Patients were randomly assigned to rhBNP (n=25) and control (n=23) groups. In addition to standard therapy, study group individuals received rhBNP by continuous infusion at 0.005 µg kg−1 min−1 for 72 hours. RESULTS: Baseline characteristics, medications, and peak of cardiac troponin I (cTnI) were similar between both groups. rhBNP treatment resulted in consistently improved pulmonary capillary wedge pressure (PCWP) compared to the control group. Respectively, 7 and 9 patients died in experimental and control groups. No drug-related serious adverse events occurred in either group. CONCLUSION: When added to standard care in stable patients with cardiogenic shock complicating anterior STEMI, low dose rhBNP improves PCWP and is well tolerated.


Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Peptídeo Natriurético Encefálico/administração & dosagem , Infarto Miocárdico de Parede Anterior/tratamento farmacológico , Intervenção Coronária Percutânea/mortalidade , Infarto do Miocárdio com Supradesnível do Segmento ST/tratamento farmacológico , Choque Cardiogênico/etiologia , Pressão Sanguínea/efeitos dos fármacos , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/farmacologia , Pressão Propulsora Pulmonar/efeitos dos fármacos , Análise de Variância , Peptídeo Natriurético Encefálico/uso terapêutico , Peptídeo Natriurético Encefálico/farmacologia , Infarto Miocárdico de Parede Anterior/complicações , Infarto Miocárdico de Parede Anterior/mortalidade , Infarto do Miocárdio com Supradesnível do Segmento ST/complicações , Infarto do Miocárdio com Supradesnível do Segmento ST/mortalidade , Frequência Cardíaca/efeitos dos fármacos , Balão Intra-Aórtico/métodos
2.
Rev. chil. obes ; 6(1): 5-15, 2001. tab
Artigo em Espanhol | LILACS | ID: lil-314845

RESUMO

In the last decade, specially after the discovery of leptin, several neuropeptides that regulate energy intake and expenditure have been described in animal models. This has partially unvelied the underlying mechanisms that regulate body composition and weight and therefore a promise of a more effective treatment of obesity and its comorbidities is ad portas


Assuntos
Humanos , Diabetes Mellitus Tipo 2 , Resistência à Insulina , Obesidade , Regulação do Apetite/genética , Ácidos Graxos/genética , Acilação , Diabetes Mellitus Tipo 2 , Dopamina , Fator Natriurético Atrial/farmacologia , Hipertensão/etiologia , Leptina , Lipólise , Biologia Molecular , Mutação/genética , Neuropeptídeos/farmacologia , Obesidade , Peptídeo Natriurético Encefálico/farmacologia , Peptídeo Natriurético Tipo C/farmacologia , Proliferadores de Peroxissomos , Proteínas Tirosina Fosfatases/farmacologia , Receptores Adrenérgicos beta/genética , Desacopladores
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA